Shares of Tesaro, a small pharmaceutical industry in the United States increased by 82% this week after the company announced a drug that decreases the growth rate of tumors in the ovaries.
In a test with 500 volunteer patients, the company's researchers found that niraparib inhibits the development of cancerous polyps.
The company plans to sell the medically in the United States and Europe by the end of the year. The discovery is a great victory of the chief executive of the company, Lonnie Moulder, who managed to sell his last company, MGI Pharma, Eisai for $ 3.9 billion.
Another victory is the class of medicines called PARP inhibitors, which work by destroying the ability of cells to repair their DNA, a function that damages cancer cells.
The study was done with patients who had already received other medicines that stop the growth of tumors. The niparib served to prevent them grow again.
Several companies are developing other types of PARP inhibitors, but at different stages of the disease.
Leerink research agency analysts estimate that niparib sales may reach $ 323 million by 2018 and spend $ 1 billion by 2021.
Nenhum comentário:
Postar um comentário